Navigation Links
New treatment approach to rare cancer results in prolonged survival
Date:5/26/2010

CHICAGO -- Aggressive treatment of anaplastic thyroid carcinoma has dramatically increased survival in the small group of patients who chose to undergo it, say physicians at Mayo Clinic. Their findings will be presented at the annual meeting of the American Society of Clinical Oncology, to be held June 4-8 in Chicago.

Mayo oncologists say this new approach reflects the need to aggressively treat metastasis even when this rare cancer seems to be confined to the neck. Historically, anaplastic thyroid cancer has been treated with surgery and radiation, but due to rapid spread of microscopic cancer, only between 10 and 20 percent of patients survive past a year. Because the prognosis for this cancer is so poor, Mayo physicians felt that a more aggressive pilot approach that added in chemotherapy early on was merited.

Of 24 patients with newly diagnosed anaplastic thyroid cancer seen at Mayo Clinic between 2003 and 2007, 10 patients with local disease elected to pursue the aggressive approach. After surgery, the patients were treated with intensity modulated radiation therapy (IMRT), a more tailored form of radiation therapy than has been used before, and with aggressive chemotherapy (docetaxel and doxorubicin) in efforts to simultaneously control disease in the neck and forestall metastasis.

One-year survival in this group was 70 percent, with six of the 10 patients (60 percent) alive at least two years post-treatment -- five of them without evidence of disease. Two of these patients were treated more than three years ago and are still in remission.

"The results are far superior to what we have seen before or even expected were possible," says Keith Bible, M.D., Ph.D., a lead investigator of the study, along with Robert Foote, M.D., and Julian Molina, M.D., Ph.D.

However, the benefits come at the cost of toxicity, the researchers add.

"Toxicity is a very real issue, to the point that many patients required hospitalization related to side effects from the therapy, but no deaths resulted from therapy," says Dr. Bible, who is presenting the results. Of the four patients who have died to date, all succumbed to their disease, not to treatment effects.

Dr. Bible added that a clinical trial formally testing two approaches to the addition of chemotherapy to radiotherapy in a randomized fashion will be launched in the fall and will include other centers nationwide. The new study will use a related chemotherapy drug, paclitaxel, as well as the addition of a targeted therapy. Dr. Bible will co-lead the study along with Eric Sherman, M.D., from Memorial Sloan-Kettering Cancer Center and others.

Mayo Clinic is regarded as a center of excellence for the treatment of anaplastic thyroid cancer due to the clinic's specialization in thyroid and endocrine cancers -- an expertise that dates back to the practice of thyroid surgeon Charles H. Mayo, M.D., one of the founders of Mayo Clinic. "We have become seriously focused on how to treat these and other rare endocrine cancers more effectively," Dr. Bible says.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Visually guided laser may be viable treatment for abnormal heartbeat
2. Hands-on osteopathic treatment cuts hospital stays for pneumonia patients
3. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
4. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
5. Exercise may keep cancer patients healthier during, after treatment
6. Smoking cessation treatments work and are safe for people with severe mental illness
7. What is the best treatment for children with vesicoureteral reflux?
8. Post-Chemo Treatment May Boost Lung Cancer Survival
9. Book Delivers Latest ADHD Research, Treatments & Results
10. Early Treatment With Clot-Busting Drug Best After Stroke
11. CIGNA and Cancer Treatment Centers of America Reach New Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... seniors, today announced rapid completion of the strategic executive team expansion needed to ... additions to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive ...
(Date:3/23/2017)... , ... March 23, 2017 , ... Inflow IQ & ... is serious so build on a solid foundation. As experts in dangerous situations ... information that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Force Dagger Foundation the US Special Operations Command’s Patriot Award. The award was ... Thomas thanked Task Force Dagger Foundation for its significant and enduring support to ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a ... Back” is the creation of published author Bonetta Rose, a wife, mother and grandmother ... , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger ... fiction writer with an active imagination and an enthusiasm for action and adventure stories. ... of Wild Bill Hart, who sat looking at the thirty-three notches that lined the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017   Casetabs , the pioneer surgery coordination ... for the iPhone. With this new release, Casetabs is ... for physician offices, ambulatory surgery centers (ASCs) and hospitals. ... users even faster, more reliable access to case information. ... to connect care teams so that surgeries can be ...
(Date:3/23/2017)... LUND, Sweden , Mar 23, 2017 ... mitochondrial medicine company, today announced that the English version of ... company,s website www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical ... committed to the discovery and development of medicines that preserve ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Respiratory care devices Market ... the next decade to reach approximately $38.27 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology: